Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial

To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.

Inclusion Criteria:

• Female, age≥18 years old
• ECOG≤2
• Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions
• HR+/HER2+ or HR-/HER2+ or HR-/HER2-
• At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
• Disease control (complete response + partial response + stable disease) after salvage treatment
• Expected survival ≥6 months
• Adequate organ function

Exclusion Criteria:

• during pregnancy and lactation
• Patients with central nervous system metastasis